3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Neoplasm Metastasis
1
Metastatic Gastric Adenocarcinoma
1
Liver Neoplasms
1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Junction Adenocarcinoma
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Sorafenib
8
durvalumab
4
Cisplatin
4
Gemcitabine
3
Ethiodized Oil
3
Doxorubicin
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
tremelimumab
2
sodium thiosulfate
2
phosphomannopentaose sulfate
2
Watchful Waiting
2
Talaporfin
2
Radiofrequency Ablation
2
Oxaliplatin
2
Nivolumab
2
Folfox protocol
2
Celecoxib
2
Capecitabine
2
Analgesia, Patient-Controlled
2
seocalcitol
1
parecoxib
1
nolatrexed
1
linifanib
1
lenvatinib
1
ferumoxides
1
ferric carboxymaltose
1
contrast agent BR1
1
cabozantinib
1
brivanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Liver Neoplasms
×
Ramucirumab
×
Clear all
NCT02435433
2023-01-20
REACH-2
Eli Lilly and Company
Phase 3
Completed
399 enrolled
22 charts
1 FDA